Topics:
Breast Cancer • Radiation Oncology
Is there any data to support SLNB instead of ALND in patients with clinically N2-3 breast cancer after neoadjuvant chemotherapy?
Alliance Z-1071 cohort had 5% with cN2 and <1% fixed or matted and the current Alliance trial 011202 only allows cN1. ALND has never been shown to improve survival.
Answer from: Radiation Oncologist at Community Practice
The sentina trial and acsog trial had Predominant N1 disease and negative predictive value Of SNLN is not known for N2 or N3 disease
Sign in or Register to read more